{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:11:26Z","timestamp":1790892686473,"version":"4.1.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.4065\/84.2.161","type":"journal-article","created":{"date-parts":[[2009,1,30]],"date-time":"2009-01-30T23:25:35Z","timestamp":1233357935000},"page":"161-169","source":"Crossref","is-referenced-by-count":33,"title":["Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy?"],"prefix":"10.4065","volume":"84","author":[{"given":"Elias","family":"Jabbour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9584","key":"10.4065\/84.2.161_bib1","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"Chronic myeloid leukaemia","volume":"370","author":"Hehlmann","year":"2007","journal-title":"Lancet"},{"issue":"6","key":"10.4065\/84.2.161_bib2","first-page":"1972","article-title":"Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase","volume":"9","author":"Johnson","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.4065\/84.2.161_bib3","series-title":"Gleevec (imatinib mesylate)[package insert]","year":"2007"},{"issue":"23","key":"10.4065\/84.2.161_bib4","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"10.4065\/84.2.161_bib5","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/blood-2006-02-004325","article-title":"Survival benefit with imatinib mesylate versus interferon-\u03b1-based regimens in newly diagnosed chronic phase chronic myelogenous leukemia","volume":"108","author":"Kantarjian","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.4065\/84.2.161_bib6","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"6","key":"10.4065\/84.2.161_bib7","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study","volume":"99","author":"Talpaz","year":"2002","journal-title":"Blood"},{"issue":"10","key":"10.4065\/84.2.161_bib8","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.4065\/84.2.161_bib9","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/cncr.23238","article-title":"Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?","volume":"112","author":"Kantarjian","year":"2008","journal-title":"Cancer"},{"issue":"8","key":"10.4065\/84.2.161_bib10","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/cncr.20922","article-title":"Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up","volume":"103","author":"Lahaye","year":"2005","journal-title":"Cancer"},{"issue":"10","key":"10.4065\/84.2.161_bib11","first-page":"1117","article-title":"Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients","volume":"88","author":"Cervantes","year":"2003","journal-title":"Haematologica"},{"issue":"12","key":"10.4065\/84.2.161_bib12","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1038\/sj.leu.2403158","article-title":"Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase","volume":"17","author":"Branford","year":"2003","journal-title":"Leukemia"},{"issue":"1","key":"10.4065\/84.2.161_bib13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.blre.2005.01.008","article-title":"Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia","volume":"20","author":"Hughes","year":"2006","journal-title":"Blood Rev"},{"issue":"6","key":"10.4065\/84.2.161_bib14","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1046\/j.1365-2141.2003.04200.x","article-title":"The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia","volume":"120","author":"Wang","year":"2003","journal-title":"Br J Haematol"},{"issue":"6","key":"10.4065\/84.2.161_bib15","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.4065\/84.2.161_bib16","author":"National Comprehensive Cancer Network (NCCN)"},{"issue":"11, pt 1","key":"10.4065\/84.2.161_bib17","doi-asserted-by":"crossref","first-page":"573a","DOI":"10.1182\/blood.V110.11.1932.1932","article-title":"Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in long-term outcome for patients (Pts) with chronic phase (CP) chronic myeloid leukemia (CML) [abstract 1932]","volume":"110","author":"Alvarado","year":"2007","journal-title":"Blood"},{"issue":"12","key":"10.4065\/84.2.161_bib18","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","article-title":"European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor","volume":"112","author":"Marin","year":"2008","journal-title":"Blood"},{"issue":"suppl 2","key":"10.4065\/84.2.161_bib19","doi-asserted-by":"crossref","first-page":"ii63","DOI":"10.1093\/annonc\/mdn091","article-title":"Chronic myelogenous leukemia: ESMO clinical recommendations for the diagnosis, treatment and follow-up","volume":"19","author":"Hochhaus","year":"2008","journal-title":"Ann Oncol"},{"issue":"4","key":"10.4065\/84.2.161_bib20","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1182\/blood-2007-09-110189","article-title":"Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods","volume":"111","author":"Kantarjian","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.4065\/84.2.161_bib21","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"issue":"9","key":"10.4065\/84.2.161_bib22","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1182\/blood-2004-03-1134","article-title":"Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations","volume":"104","author":"Branford","year":"2004","journal-title":"Blood"},{"issue":"20","key":"10.4065\/84.2.161_bib23","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1158\/1078-0432.CCR-07-1112","article-title":"A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response","volume":"13","author":"Press","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.4065\/84.2.161_bib24","first-page":"235","article-title":"The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia","volume":"91","author":"Wang","year":"2006","journal-title":"Haematologica"},{"issue":"11","key":"10.4065\/84.2.161_bib25","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1182\/blood-2005-11-4406","article-title":"BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML","volume":"107","author":"Press","year":"2006","journal-title":"Blood"},{"issue":"7","key":"10.4065\/84.2.161_bib26","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance and the road to a cure of chronic myeloid leukemia","volume":"110","author":"O'Hare","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.4065\/84.2.161_bib27","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/blood-2005-03-1036","article-title":"High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy","volume":"106","author":"Willis","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.4065\/84.2.161_bib28","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/sj.leu.2404137","article-title":"The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib","volume":"20","author":"Khorashad","year":"2006","journal-title":"Leukemia"},{"issue":"1","key":"10.4065\/84.2.161_bib29","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"issue":"29","key":"10.4065\/84.2.161_bib30","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1200\/JCO.2008.16.9953","article-title":"Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression","volume":"26","author":"Khorashad","year":"2008","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.4065\/84.2.161_bib31","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/cncr.22523","article-title":"Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Cancer"},{"issue":"2","key":"10.4065\/84.2.161_bib32","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2002-05-1451","article-title":"Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia","volume":"101","author":"Kantarjian","year":"2003","journal-title":"Blood"},{"issue":"11, pt 1","key":"10.4065\/84.2.161_bib33","first-page":"317a","article-title":"Imatinib dose escalation is effective in patients with chronic myeloid leukemia in chronic phase (CML-CP) [abstract 1047]","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"issue":"11, pt 1","key":"10.4065\/84.2.161_bib34","doi-asserted-by":"crossref","first-page":"313a","DOI":"10.1182\/blood.V110.11.1035.1035","article-title":"Impact of imatinib mesylate dose escalation on resistance and sub-optimal responses to standard-dose therapy in patients (pts) with chronic myeloid leukemia (CML) [abstract 1035]","volume":"110","author":"Jabbour","year":"2007","journal-title":"Blood"},{"issue":"11, pt 1","key":"10.4065\/84.2.161_bib35","doi-asserted-by":"crossref","first-page":"318a","DOI":"10.1182\/blood.V110.11.1052.1052","article-title":"Imatinib mesylate dose escalation improves disease response in chronic-phase chronic myeloid leukaemia patients after cytogenetic or molecular suboptimal responses to standard doses of imatinib [abstract 1052]","volume":"110","author":"Rea","year":"2007","journal-title":"Blood"},{"issue":"11, pt 1","key":"10.4065\/84.2.161_bib36","first-page":"871a","article-title":"Efficacy of imatinib mesylate dose-escalation in CML patients showing suboptimal response to standard dose [abstract 2967]","volume":"110","author":"Kim","year":"2007","journal-title":"Blood"},{"issue":"7","key":"10.4065\/84.2.161_bib37","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1182\/blood-2003-06-2042","article-title":"Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses [letter]","volume":"102","author":"Marin","year":"2003","journal-title":"Blood"},{"issue":"6","key":"10.4065\/84.2.161_bib38","first-page":"2092","article-title":"The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment","volume":"9","author":"Zonder","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.4065\/84.2.161_bib39","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1080\/10428190701474381","article-title":"Efficacy of dose escalation of imatinib mesylate in patients with cytogenetic or hematologic resistance [letter]","volume":"48","author":"Sohn","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.4065\/84.2.161_bib40","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1182\/asheducation-2005.1.183","article-title":"Loss of response to imatinib: mechanisms and management","author":"Shah","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"8","key":"10.4065\/84.2.161_bib41","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"issue":"8","key":"10.4065\/84.2.161_bib42","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"issue":"9","key":"10.4065\/84.2.161_bib43","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nrd2135","article-title":"Dasatinib","volume":"5","author":"Kantarjian","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.4065\/84.2.161_bib44","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1158\/1078-0432.CCR-07-4175","article-title":"Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate","volume":"14","author":"Brave","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.4065\/84.2.161_bib45","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res"},{"issue":"6","key":"10.4065\/84.2.161_bib46","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy [published correction appears in Blood. 2007;110 (5):1438]","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"issue":"10","key":"10.4065\/84.2.161_bib47","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","article-title":"Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase","volume":"109","author":"Guilhot","year":"2007","journal-title":"Blood"},{"issue":"8","key":"10.4065\/84.2.161_bib48","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","article-title":"Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis","volume":"109","author":"Cortes","year":"2007","journal-title":"Blood"},{"issue":"12","key":"10.4065\/84.2.161_bib49","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"issue":"11, pt 1","key":"10.4065\/84.2.161_bib50","doi-asserted-by":"crossref","first-page":"225a","DOI":"10.1182\/blood.V110.11.734.734","article-title":"Efficacy of dasatinib in patients with chronic-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-C (CA180-013) [abstract 734]","volume":"110","author":"Stone","year":"2007","journal-title":"Blood"},{"issue":"11, pt 1","key":"10.4065\/84.2.161_bib51","doi-asserted-by":"crossref","first-page":"145a","DOI":"10.1182\/blood.V110.11.470.470","article-title":"Efficacy of dasatinib in patients with accelerated-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-A (CA180-005) [abstract 470]","volume":"110","author":"Guilhot","year":"2007","journal-title":"Blood"},{"issue":"11, pt 1","key":"10.4065\/84.2.161_bib52","doi-asserted-by":"crossref","first-page":"145a","DOI":"10.1182\/blood.V110.11.472.472","article-title":"Efficacy and safety of dasatinib in patients with chronic myeloid leukemia in blast phase whose disease is resistant or intolerant to imatinib: 2-year follow-up data from the START program [abstract 472]","volume":"110","author":"Gambacorti","year":"2007","journal-title":"Blood"},{"issue":"11, pt 1","key":"10.4065\/84.2.161_bib53","doi-asserted-by":"crossref","first-page":"226a","DOI":"10.1182\/blood.V110.11.736.736","article-title":"Dasatinib or high-dose imatinib for patients with chronic-phase chronic myeloid leukemia resistant to standard-dose imatinib: 2-year follow-up data from START-R (CA180-017) [abstract 736]","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"issue":"11, pt 1","key":"10.4065\/84.2.161_bib54","first-page":"226a","article-title":"Nilotinib is highly active and safe in chronic phase chronic myelogenous leukemia (CML-CP) patients with imatinib-resistance or intolerance [abstract 735]","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"issue":"4","key":"10.4065\/84.2.161_bib55","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia","volume":"111","author":"le Coutre","year":"2008","journal-title":"Blood"},{"issue":"11, pt 1","key":"10.4065\/84.2.161_bib56","first-page":"310a","article-title":"Nilotinib in patients (pts) with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib [abstract 1025]","volume":"110","author":"Giles","year":"2007","journal-title":"Blood"},{"issue":"5682","key":"10.4065\/84.2.161_bib57","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"issue":"11","key":"10.4065\/84.2.161_bib58","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants","volume":"66","author":"Tokarski","year":"2006","journal-title":"Cancer Res"},{"issue":"3","key":"10.4065\/84.2.161_bib59","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3324\/haematol.10822","article-title":"Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain","volume":"92","author":"Soverini","year":"2007","journal-title":"Haematologica"},{"issue":"9","key":"10.4065\/84.2.161_bib60","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","article-title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency","volume":"117","author":"Shah","year":"2007","journal-title":"J Clin Invest"},{"issue":"4","key":"10.4065\/84.2.161_bib61","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1182\/blood-2007-06-096396","article-title":"In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib","volume":"111","author":"Khorashad","year":"2008","journal-title":"Blood"},{"issue":"12","key":"10.4065\/84.2.161_bib62","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","article-title":"Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors","volume":"110","author":"Cortes","year":"2007","journal-title":"Blood"},{"issue":"19","key":"10.4065\/84.2.161_bib63","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia","volume":"26","author":"Shah","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.4065\/84.2.161_bib64","series-title":"SPRYCEL [package insert]","year":"2007"},{"issue":"2","key":"10.4065\/84.2.161_bib65","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"issue":"10","key":"10.4065\/84.2.161_bib66","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"issue":"11, pt 1","key":"10.4065\/84.2.161_bib67","doi-asserted-by":"crossref","first-page":"145a","DOI":"10.1182\/blood.V110.11.471.471","article-title":"Nilotinib is safe and effective in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib resistance or intolerance [abstract 471]","volume":"110","author":"le Coutre","year":"2007","journal-title":"Blood"},{"key":"10.4065\/84.2.161_bib68","series-title":"Tasigna (nilotinib) [package insert]","year":"2007"},{"issue":"11, pt 1","key":"10.4065\/84.2.161_bib69","first-page":"311a","article-title":"Nilotinib therapy after dasatinib failure in patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) [abstract 1029]","volume":"110","author":"Giles","year":"2007","journal-title":"Blood"},{"issue":"11, pt 1","key":"10.4065\/84.2.161_bib70","doi-asserted-by":"crossref","first-page":"101a","DOI":"10.1182\/blood.V110.11.320.320","article-title":"Responses and disease progression in CML-CP patients treated with nilotinib after imatinib failure appear to be affected by the BCR-ABL mutation status and types [abstract 320]","volume":"110","author":"Hughes","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.4065\/84.2.161_bib71","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2008.84","article-title":"Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib","volume":"22","author":"Hochhaus","year":"2008","journal-title":"Leukemia"},{"issue":"25","key":"10.4065\/84.2.161_bib72","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","article-title":"Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure","volume":"25","author":"Quint\u00e1s-Cardama","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.4065\/84.2.161_bib73","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2141.2008.07108.x","article-title":"Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis [letter]","volume":"141","author":"de Lavallade","year":"2008","journal-title":"Br J Haematol"},{"issue":"8","key":"10.4065\/84.2.161_bib74","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.bbmt.2006.03.012","article-title":"Role of allogeneic stem cell transplantation for adult chronic myeloid leukemia in the imatinib era","volume":"12","author":"Grigg","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.4065\/84.2.161_bib75","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1002\/cncr.22569","article-title":"Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Cancer"},{"issue":"4","key":"10.4065\/84.2.161_bib76","first-page":"452","article-title":"The effect of prior exposure to imatinib on transplant-related mortality","volume":"91","author":"Deininger","year":"2006","journal-title":"Haematologica"},{"issue":"2","key":"10.4065\/84.2.161_bib77","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/cncr.22778","article-title":"Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity","volume":"110","author":"Jabbour","year":"2007","journal-title":"Cancer"},{"issue":"8","key":"10.4065\/84.2.161_bib78","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1182\/blood-2008-02-141689","article-title":"Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia","volume":"112","author":"Lee","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.4065\/84.2.161_bib79","first-page":"375","article-title":"SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice","volume":"63","author":"Golas","year":"2003","journal-title":"Cancer Res"},{"issue":"11, pt 1","key":"10.4065\/84.2.161_bib80","doi-asserted-by":"crossref","first-page":"146a","DOI":"10.1182\/blood.V110.11.473.473","article-title":"Bosutinib (SKI-606) demonstrates clinical activity and is well tolerated among patients with AP and BP CML and Ph+ ALL [abstract 473]","volume":"110","author":"Gambacorti-Passerini","year":"2007","journal-title":"Blood"},{"issue":"12","key":"10.4065\/84.2.161_bib81","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1182\/blood-2005-06-2209","article-title":"NS-187, a potent and selective dual Bcr-Abl\/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia","volume":"106","author":"Kimura","year":"2005","journal-title":"Blood"},{"issue":"11, pt 1","key":"10.4065\/84.2.161_bib82","doi-asserted-by":"crossref","first-page":"144a","DOI":"10.1182\/blood.V110.11.469.469","article-title":"A phase I study of INNO-406 in patients with advanced Philadelphia (Ph+) chromosome-positive leukemias who are resistant or intolerant to imatinib and second generation tyrosine kinase inhibitors [abstract 469]","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.4065\/84.2.161_bib83","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2006-05-025049","article-title":"MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation","volume":"109","author":"Giles","year":"2007","journal-title":"Blood"},{"issue":"s1","key":"10.4065\/84.2.161_bib84","first-page":"47","article-title":"Interim results from a phase I clinical trial of the BCR-ABL inhibitor XL228 in drug-resistant Ph+ leukemias [abstract 120]","volume":"93","author":"Shah","year":"2008","journal-title":"Haematologica"},{"issue":"5","key":"10.4065\/84.2.161_bib85","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1182\/blood-2002-07-1973","article-title":"Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.4065\/84.2.161_bib86","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/cncr.22398","article-title":"Phase I\/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy","volume":"109","author":"Quint\u00e1s-Cardama","year":"2007","journal-title":"Cancer"},{"issue":"6","key":"10.4065\/84.2.161_bib87","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/cncr.22901","article-title":"Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib","volume":"110","author":"Cortes","year":"2007","journal-title":"Cancer"},{"issue":"17","key":"10.4065\/84.2.161_bib88","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1200\/JCO.2005.11.981","article-title":"Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate","volume":"23","author":"Issa","year":"2005","journal-title":"J Clin Oncol"},{"issue":"11, pt 1","key":"10.4065\/84.2.161_bib89","doi-asserted-by":"crossref","first-page":"16a","DOI":"10.1182\/blood.V110.11.27.27","article-title":"Time to complete cytogenetic response (CCyR) does not affect long-term outcomes for patients on imatinib therapy [abstract 27]","volume":"110","author":"Guilhot","year":"2007","journal-title":"Blood"},{"issue":"11, pt 1","key":"10.4065\/84.2.161_bib90","doi-asserted-by":"crossref","first-page":"314a","DOI":"10.1182\/blood.V110.11.1036.1036","article-title":"Importance of early intervention with dasatinib at cytogenetic rather than hematologic resistance to imatinib [abstract 1036]","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.4065\/84.2.161_bib91","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3324\/haematol.11993","article-title":"Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib","volume":"93","author":"Ernst","year":"2008","journal-title":"Haematologica"},{"issue":"3","key":"10.4065\/84.2.161_bib92","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1182\/blood-2008-02-141580","article-title":"Failure to achieve a major cytogenetic response by twelve months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611608240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611608240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T06:36:43Z","timestamp":1589524603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611608240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":92,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["S0025619611608240"],"URL":"https:\/\/doi.org\/10.4065\/84.2.161","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2009,2]]}}}